HEALTH.2013.2.3.1-1
HEALTH.2013.2.3.1-1
7 projects · €35,489,573 total EU contribution (project-level) · 33 participating organizations · 12 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€35,489,573
Countries active
Participant organizations by country (headquarters in CORDIS).
- France (7)
- UK (6)
- Germany (3)
- Spain (3)
- Italy (3)
- BE (2)
- CH (2)
- DK (2)
- SE (2)
- IE (1)
- LV (1)
- Netherlands (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- BKE1 projects · IE
- C.RIS PHARMA1 projects · FR
- CHUV1 projects · CH
- LAB1 projects · DK
- CLEAN CELLS1 projects · FR
- IDIBAPS-CERCA1 projects · ES
- ECOLE ROYALE MILITAIRE - KONINKLIJKE MILITAIRE SCHOOL1 projects · BE
- ERASMUS MC1 projects · NL
- EUROPEAN VACCINE INITIATIVE1 projects · DE
- F2G1 projects · UK
- FGK1 projects · DE
- IMAXIO1 projects · FR
Projects
Page 1 of 1
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
New AntiBacterials with Inhibitory activity on Aminoacyl-tRNA Synthetases NABARSI · 601725 | FP7 | €4,102,158 | €5,372,277 | Details |
Evaluation of phage therapy for the treatment of Escherichia coli and Pseudomonas aeruginosa burn wound infections (Phase I-II clinical trial) PHAGOBURN · 601857 | FP7 | €3,838,422 | €4,920,436 | Details |
Oral Vaccination against Clostridium difficile Infection CDVAX · 601810 | FP7 | €5,808,757 | €7,547,624 | Details |
Development of Group B Streptococcal vaccine to alleviate emerging antibiotic resistance through elimination of current prophylactic antibiotic strategies in GBS prevention. NEOSTREP · 601743 | FP7 | €5,999,172 | €7,891,808 | Details |
Targeting the HIV-1 Nucleocapsid Protein to fight Antiretroviral Drug Resistance THINPAD · 601969 | FP7 | €5,691,950 | €7,451,081 | Details |
Novel antifungals to treat resistant organisms NOFUN · 601963 | FP7 | €4,550,286 | €6,106,868 | Details |
comBinig cELLular and humoral immunE RespOnses as a vaccine strategy against staPHhylOcoccus aureus pathogeN BELLEROPHON · 601783 | FP7 | €5,498,829 | €7,105,813 | Details |